{"title":"Nano-engineered monoclonal antibodies expanding the newer avenues for cancer targeting","authors":"Kumar Janakiraman, Gracesuganthi Jayaraj, Vaidevi Sethuraman, Venkateshwaran Krishnaswami","doi":"10.1007/s13233-024-00322-1","DOIUrl":null,"url":null,"abstract":"<div><p>The monoclonal antibodies (mAbs) selectively hinder the signaling involved in tumor growth and/or stimulate immune responses against tumor cells. Through the combination of mAbs, it is possible to target multiple pathways at the same time, which could result in additional or cooperative effects. In recent years, the method of generating mAbs from pathways individual isolated B cells has gained popularity. As of now, there are no therapeutic mAbs that have been approved by the US FDA. However, this technology has some significant benefits and the current obstacles associated with it are being addressed. The efficacy of mAbs is highly dependent on the antigen labeling methodology, the arrangement of sorting antigens (such as monomer or dimer), and the selection of primers for amplification. The use of bevacizumab in combination with cetuximab or panitumumab in advanced colorectal cancer may provide undesirable outcomes. These combinations lead to a decrease in the length of progression-free survival and an increase in toxicity when compared to therapy with only one antibody. The mAbs represent a notable example of a translational scientific breakthrough, which took around ten years to progress from laboratory use to practical clinical use. However, it is essential to assess the cost, efficacy, and safety of mAbs treatments due to their potentially high cost. This review focuses on the possibility of mAbs being delivered through nanotechnology-based formulation techniques. The emphasis is placed on recent patents that are linked to mAbs.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div><div><p>Monoclonal antibodies covalently linked to drugs and their various nanoformulations for selectively targeting different types of cancer</p></div></div></figure></div></div>","PeriodicalId":688,"journal":{"name":"Macromolecular Research","volume":"33 2","pages":"117 - 135"},"PeriodicalIF":2.8000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Macromolecular Research","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s13233-024-00322-1","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"POLYMER SCIENCE","Score":null,"Total":0}
引用次数: 0
Abstract
The monoclonal antibodies (mAbs) selectively hinder the signaling involved in tumor growth and/or stimulate immune responses against tumor cells. Through the combination of mAbs, it is possible to target multiple pathways at the same time, which could result in additional or cooperative effects. In recent years, the method of generating mAbs from pathways individual isolated B cells has gained popularity. As of now, there are no therapeutic mAbs that have been approved by the US FDA. However, this technology has some significant benefits and the current obstacles associated with it are being addressed. The efficacy of mAbs is highly dependent on the antigen labeling methodology, the arrangement of sorting antigens (such as monomer or dimer), and the selection of primers for amplification. The use of bevacizumab in combination with cetuximab or panitumumab in advanced colorectal cancer may provide undesirable outcomes. These combinations lead to a decrease in the length of progression-free survival and an increase in toxicity when compared to therapy with only one antibody. The mAbs represent a notable example of a translational scientific breakthrough, which took around ten years to progress from laboratory use to practical clinical use. However, it is essential to assess the cost, efficacy, and safety of mAbs treatments due to their potentially high cost. This review focuses on the possibility of mAbs being delivered through nanotechnology-based formulation techniques. The emphasis is placed on recent patents that are linked to mAbs.
Graphical abstract
Monoclonal antibodies covalently linked to drugs and their various nanoformulations for selectively targeting different types of cancer
期刊介绍：
Original research on all aspects of polymer science, engineering and technology, including nanotechnology
Presents original research articles on all aspects of polymer science, engineering and technology
Coverage extends to such topics as nanotechnology, biotechnology and information technology
The English-language journal of the Polymer Society of Korea
Macromolecular Research is a scientific journal published monthly by the Polymer Society of Korea. Macromolecular Research publishes original researches on all aspects of polymer science, engineering, and technology as well as new emerging technologies using polymeric materials including nanotechnology, biotechnology, and information technology in forms of Articles, Communications, Notes, Reviews, and Feature articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
